Trial Profile

A Phase III, Randomized, Two-armed, Parallel, Triple-blind, Active-controlled, Equivalency Clinical Trial of Efficacy and Safety Pertuzumab (CinnaGen Co.) Compared With Perjeta (Originator Pertuzumab) in Neoadjuvant Treatment of HER2+ Breast Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab (Primary) ; Carboplatin; Docetaxel; Trastuzumab
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Inflammatory breast cancer
Focus Registrational; Therapeutic Use
Sponsors CinnaGen

07 Sep 2022 Primary endpoint has been met. (Breast Pathological Complete Response (bpCR), as per Results published in the BMC Cancer
07 Sep 2022 Results published in the BMC Cancer
24 Feb 2020 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com